S Kurtoğlu1, N Hatipoglu2. 1. Department of Pediatric Endocrinology, Medical Faculty, Erciyes University, 38039, Kayseri, Turkey. 2. Department of Pediatric Endocrinology, Medical Faculty, Erciyes University, 38039, Kayseri, Turkey. nihalhatipoglu@yahoo.com.
Abstract
INTRODUCTION: Growth hormone resistance defines several genetic (primary) and acquired (secondary) pathologies that result in completely or partially interrupted activity of growth hormone. An archetypal disease of this group is the Laron-type dwarfism caused by mutations in growth hormone receptors. The diagnosis is based on high basal levels of growth hormone, low insulin like growth factor-I (IGF-1) level, unresponsiveness to IGF generation test and genetic testing. Recombinant IGF-1 preparations are used in the treatment CONCLUSION: In this article, clinical characteristics, diagnosis and therapeutic approaches of the genetic and other diseases leading to growth hormone insensitivity are reviewed.
INTRODUCTION:Growth hormone resistance defines several genetic (primary) and acquired (secondary) pathologies that result in completely or partially interrupted activity of growth hormone. An archetypal disease of this group is the Laron-type dwarfism caused by mutations in growth hormone receptors. The diagnosis is based on high basal levels of growth hormone, low insulin like growth factor-I (IGF-1) level, unresponsiveness to IGF generation test and genetic testing. Recombinant IGF-1 preparations are used in the treatment CONCLUSION: In this article, clinical characteristics, diagnosis and therapeutic approaches of the genetic and other diseases leading to growth hormone insensitivity are reviewed.
Authors: Horacio M Domené; Sonia V Bengolea; Alicia S Martínez; M Gabriela Ropelato; Patricia Pennisi; Paula Scaglia; Juan J Heinrich; Héctor G Jasper Journal: N Engl J Med Date: 2004-02-05 Impact factor: 91.245
Authors: Alessia David; Louise A Metherell; Adrian J L Clark; Cecilia Camacho-Hübner; Martin O Savage Journal: Endocrinol Metab Clin North Am Date: 2005-09 Impact factor: 4.741
Authors: D C Chrysis; T K Alexandrides; E Koromantzou; N Georgopoulos; P Vassilakos; W Kiess; J Kratsch; N G Beratis; B E Spiliotis Journal: Clin Endocrinol (Oxf) Date: 2001-02 Impact factor: 3.478
Authors: Helen L Storr; Sumana Chatterjee; Louise A Metherell; Corinne Foley; Ron G Rosenfeld; Philippe F Backeljauw; Andrew Dauber; Martin O Savage; Vivian Hwa Journal: Endocr Rev Date: 2019-04-01 Impact factor: 19.871